Please login to the form below
Algeta
This page shows the latest Algeta news and features for those working in and with pharma, biotech and healthcare.
Relay Therapeutics strengthens team
He has held roles for Keryx Biopharmaceutical, Algeta ASA and AVEO Oncology.
Latest news
-
Bayer CEO Dekkers points to 'outstanding' pharma growth
9bn it paid for the drug's developer Algeta last December.
-
Bayer buys Chinese consumer care company
Acquires Dihon Pharmaceutical as Algeta takeover closes. . Bayer has boosted its consumer healthcare operations in emerging markets with a deal to acquire China-based Dihon Pharmaceutical Group. ... year. By the extended deadline of February 26 the
-
Bayer agrees $2.9bn deal for Algeta to get Xofigo control
The bid represents a premium of 37 per cent over Algeta's closing price on November 25 when the initial offer was made. ... Algeta chief executive Andrew Kay said last month the drug had shown "excellent momentum" thanks to rapid endorsement by the US
-
Bayer offers $2.4bn to buy Xofigo partner Algeta
Algeta made the announcement after reports in the media suggested Bayer was offering NOK 306 per share for the company. ... One unanswered question is whether Algeta has some other hidden gems in its pipeline.
-
EU approval for Bayer’s prostate cancer drug
Bayer acquired Xofigo from Norwegian company Algeta in 2009. The deal granted full commercialisation rights in Europe to Bayer while in the US Bayer co-promotes the drug with Algeta.
More from news
Approximately 4 fully matching, plus 6 partially matching documents found.
Latest Intelligence
-
Pharma deals during June 2014
Bayer paid 50m ($68m) upfront payment with further milestones in return for global rights which should complement Xofigo (from the acquisition of Algeta). The companies will jointly fund the phase III
-
Deal Watch table for November 2013
Hyperlipidemia. 2, 600. Algeta / Bayer. Acquisition. Buys out deal for Xofigo radiotherapeutic for.
-
Pharma deals during November 2013
Algeta, has been noted as being rather ungenerous, with room for upping the offer. This takeover was an obvious tactic bringing in the key the asset, Xofigo which has been under ... with Algeta under which there was US co-promotion for 50 per cent of
More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.
Latest appointments
-
Targovax appoints chief financial officer
He also brings experience from cancer biotech Algeta ASA, and management consulting expertise from McKinsey &Company's pharma and healthcare practice.
-
Targovax appoints Oystein Soug as CEO
He has previously served as chief financial officer for Algeta, a Norwegian oncology biotech that was bought by Bayer in 2014, and spent six years at Orkla, a Norwegian consumer goods
-
Algeta execs join Targovax
Anna-Kirsti Aksnes and Tina Madsen join the firm. Norway's Targovax has added to its senior team with the appointment of two executives from Algeta. ... Aksnes was most recently VP clinical research at Algeta, which was taken over by pharma giant Bayer
More from appointments
Approximately 0 fully matching, plus 3 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- BioNTech bolsters COVID-19 vaccine capacity with Novartis deal
- Gilead agrees $21bn buyout of Immunomedics
- New medical communications agency BOLDSCIENCE launches
- Pfizer’s ALK inhibitor Lorbrena hits the mark in head-to-head lung cancer trial
- BMS eyes approval for second Opdivo combo in kidney cancer
- Moderna inks R&D agreements with Vertex and Chiesi
- FDA hands BMS and bluebird bio a priority review for ide-cel
- Janssen’s EGFR-targeting treatment regimen shows early benefit in lung cancer
- Relief Therapeutics seeks US emergency approval for COVID-19 drug
- Could formulary intelligence be your brand differentiator?
- How COVID-19 is accelerating the threat of antimicrobial resistance
- Porterhouse Medical strengthens its senior management team
PMHub
Creative Medical Research
Specialising in medical device market research and participant recruitment human factors research, our approach is people-centric. We thrive on making...
Latest intelligence
- Could formulary intelligence be your brand differentiator?
- Proprietary research, and the COVID-19 experience, shows how formulary intelligence can drive competitive advantage at launch...
- How COVID-19 is accelerating the threat of antimicrobial resistance
- Why antimicrobial resistance needs to be addressed with the same urgency as COVID-19...
- Improve clinical trials through patient journey mapping
- Could patient journey mapping be your solution to improving clinical study recruitment and retention? While awareness of clinical studies is low across the population, it’s not the only issue. It’s...
Quick links
Infographics
